Nilesh Dharwadkar

NovaLead Pharma Pvt Ltd. operates as a drug discovery research company. It discovers and develops small molecule therapeutic agents capable of multiple mechanism of action for unmet needs and diseases with limited drug options. The firm focuses at developing a balanced pipeline with a mix of new chemical entities and new indications for FDA approved drugs. The company was founded by Supreet Kiran Deshpande and Atul Sharad Aslekar in 2007 and is headquartered in Pune, India.

NovaLead Pharma Pvt Ltd. operates as a drug discovery research company. It discovers and develops small molecule therapeutic agents capable of multiple mechanism of action for unmet needs and diseases with limited drug options. The firm focuses at developing a balanced pipeline with a mix of new chemical entities and new indications for FDA approved drugs. The company was founded by Supreet Kiran Deshpande and Atul Sharad Aslekar in 2007 and is headquartered in Pune, India.

NovaLead Pharma Pvt Ltd. operates as a drug discovery research company. It discovers and develops small molecule therapeutic agents capable of multiple mechanism of action for unmet needs and diseases with limited drug options. The firm focuses at developing a balanced pipeline with a mix of new chemical entities and new indications for FDA approved drugs. The company was founded by Supreet Kiran Deshpande and Atul Sharad Aslekar in 2007 and is headquartered in Pune, India.

NovaLead Pharma Pvt Ltd. operates as a drug discovery research company. It discovers and develops small molecule therapeutic agents capable of multiple mechanism of action for unmet needs and diseases with limited drug options. The firm focuses at developing a balanced pipeline with a mix of new chemical entities and new indications for FDA approved drugs. The company was founded by Supreet Kiran Deshpande and Atul Sharad Aslekar in 2007 and is headquartered in Pune, India.

NovaLead Pharma Pvt Ltd. operates as a drug discovery research company. It discovers and develops small molecule therapeutic agents capable of multiple mechanism of action for unmet needs and diseases with limited drug options. The firm focuses at developing a balanced pipeline with a mix of new chemical entities and new indications for FDA approved drugs. The company was founded by Supreet Kiran Deshpande and Atul Sharad Aslekar in 2007 and is headquartered in Pune, India.